Skip to main content
☰
moat
keep
Markets
News
Screener
Research
Editorials
Pricing
About
⌘K
Sign in
Start free
Atrium Therapeutics, Inc. (RNA) stock — financials, valuation and filings | Moatkeep
Companies
/
Nasdaq
/
RNA
Atrium Therapeutics, Inc.
RNA · Nasdaq
$10.21
−1.45%
Close, 2026-09-14
Close, 2026-09-14 · source: Databento · USD · figures not investment advice
+ Alert
★ Watchlist
Overview
News
Valuation
Financials
Reports
Editorials & Research
Business
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
MAX
⤢ Expand
Price
▾
Log
Volume
Events
▾
Window
-75.3%
vs high
-86.0%
Price
through 2026-09-14
ex-date (0) · fiscal quarter (0)
Dividends: company filings (SEC EDGAR) and the historical exchange record.
State of incorporation
DE
Fiscal year end
Dec 31
Financials · five years
Investor
Revenue
•••••
•••••
•••••
Gross profit
•••••
•••••
•••••
Operating income
•••••
•••••
•••••
Net income
•••••
•••••
•••••
Free cash flow
•••••
•••••
•••••
Investor
Read the full financial statements
Free accounts read five years of annual financials.
Create a free account
Source: SEC EDGAR (XBRL) · figures in USD millions
View full financials →
Related companies
PLX
—
Protalix BioTherapeutics, Inc.
SRI
—
STONERIDGE INC
ACU
—
ACME UNITED CORP
ANNX
—
Annexon, Inc.
IMMR
—
IMMERSION CORP
DTIL
—
PRECISION BIOSCIENCES INC
CMT
—
CORE MOLDING TECHNOLOGIES INC
IMUX
—
IMMUNIC, INC.